ApHER has presented results from the CEDAR Study in the poster “The past, present, and future of prostate cancer incidence, mortality and prevalence in Denmark during 2006 through 2030” at the 11th European Multidisciplinary Congress on Urological Cancer (EMUC19) 15-17 November, 2019.
Thanks for the large attendance during our breakout session at ISPOR in Copenhagen regarding pooling Nordic register data! We find it rewarding to share our experiences and our extensive know-how from 10 years of doing these unique studies. ApHER also presented two posters during the conference, using Danish data on Sclerosis in one study and Swedish [...]
The Danish media "Onkologisk Tidsskrift" has written an article about the findings of our CEDAR study, which was presented at the World Conference on Lung Cancer 2019. Read the full article (in Danish) here: https://onkologisktidsskrift.dk/behandlinger/lungekraeft/1271-hospitalerne-vil-se-langt-flere-patienter-med-ikke-smacellet-lungekraeft-i-fremtiden.html?user=jh64DgT&passw=%242y%2410%242i%2Fk%2FSyv55jqOqZzvPpq5uAtxVLLNnKwXSNOWEQCp%2FBOp3PyAw2Iu
ApHER was present at the IASLC 2019 World Conference on Lung Cancer in Barcelona (September 7-10 2019) with the poster "The Past, Present, and Future of SCLC and NSCLC Incidence, Mortality, and Prevalence in Denmark during 2006 through 2000”, with some of the results from the ongoing Cancer Impact in Denmark (CEDAR) Study.
Prof. Anders Green at the 5th International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications
Is diabetes per se a risk factor for developing cancer? Or is diabetes a marker of an underlying (pre-clinical) cancer process? Professor Anders Green from ApHER gave an invited presentation exploring these questions at the 5th International Conference on Interdisciplinary Management of Diabetes which took place the 7th to 9th of March in Bucharest, Romania. Read [...]
New publication: Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries.
By pooling Nordic health data on medical devices & pharmaceuticals, and analyzing it on the micro-level, we tap into the full potential of big data. The Nordic health registers cover 26 mill. people from birth to death. Read about our most recent safety study, pooling data from 4 Nordic countries, here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773955/
ApHER participated at the cancer research days presenting the CEDAR study, a nationwide, observational study including all patients living with cancer of the lung, breast, bladder, ovary, and prostate as of 31st December 2005 and all patients first-time diagnosed from then up to 31st December 2015. Patients are followed from date of first diagnosis until death [...]
ApEHR has produced a report on behalf on the Danish Multidisciplinary Cancer Groups (DMCG) and the Danish Clinical Registries (RKKP, Regionernes Kliniske Kvalitets-udviklingsprogram) with an analysis of survival over the period 1995-2014 for five major cancer forms in Denmark. The report has now been published and can be found by following the link.
Real life treatment patterns and outcomes in advanced Melanoma patients in Italy and Sweden: The development of a Multi Country Database
This pilot study aims to create an international data platform for real world data on malignant melanoma treatment which can be used in clinical and epidemiological studies to systematically observe and describe patient treatment processes and outcomes. Findings from this pilot study are presented in the poster.
In collaboration, Dr. Hans Martens and APEHR have completed a blog discussing the challenge of chronic disease for Europe's health systems. Link to the blog.